5h agoInvesting.com Analyst RatingsBULLISH 64Analyst
Raymond James raises Edgewise Therapeutics price target on FDA feedback
Raymond James raises Edgewise Therapeutics price target on FDA feedback
Why Is EDGEWISE THERAPEUTIC (EWTX) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 3:44 PM ET · reviewed against 7 wire stories
EDGEWISE THERAPEUTIC (EWTX) is drawing unusual attention today. Our newswire has captured 7 stories on EWTX across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
EWTX stock is down 6.98% at $43.20 as of the close of the session. The decline follows a report of disappointing second-quarter earnings and a series of recent insider sales. Despite a raised price target from JPMorgan, the stock is trading near its 52-week low amid ongoing pressure from bearish analysts and weak fundamental performance.
What Happened
Edgewise Therapeutics reported Q2 earnings per share of $(0.53), missing the estimated $(0.47) loss. The company remains unprofitable with a trailing twelve-month EPS of -1.85. JPMorgan raised its price target for EWTX to $60 from $53, but the move failed to offset broader skepticism. Goldman Sachs also raised its price target to $36 while maintaining a neutral stance. Meanwhile, Evercore ISI Group and Guggenheim raised their price targets to $55 and $51 respectively, and Oppenheimer initiated coverage with an outperform rating and a $51 price target. Despite these analyst actions, the stock fell sharply during the session, closing near its intraday low.
Three top executives, Kevin Koch, Joanne M. Donovan, and Alan J. Russell, sold shares on August 12, 2026. Over the past 90 days, insiders have sold a total of $9.8 million worth of shares with no insider purchases recorded.
What The Data Shows
The stock opened at $46.63 and reached a high of $46.64 shortly after the market opened. It declined steadily throughout the session, hitting a low of $43.20 at 3:40 PM ET. Trading volume of 0.3 million shares is 0.2 times the 3-month daily average. The stock closed near its 52-week low, having printed 41 fresh 52-week lows on August 20, 2026. The 30-day average sentiment score is 59/100, while the 7-day average is 68/100, indicating a recent improvement in market sentiment.
What To Watch
The stock is currently unprofitable with a market cap of $4.8 billion. Investors should monitor the company’s next earnings report if scheduled, as well as any further analyst coverage or insider activity.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
EWTX by the numbers
Coverage: 7 stories / 6 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $4.8B52w: $13.53 to $48.40
The headlines behind the move
5h agoThe FlyBULLISH 64Analyst
Edgewise Therapeutics price target raised to $85 from $66 at Raymond James
7h agoThe FlyBULLISH 64Product/PR
Edgewise Therapeutics: ‘Positive’ End-of-Phase 2 meeting with FDA for EDG-7500
7h agoStockTitanBULLISH 64Product/PR
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM...
21h agoSeeking AlphaBULLISH 74Earnings
Edgewise Therapeutics GAAP EPS of $9.65 beats by $7.15
Edgewise Therapeutics Q3 earnings beat expectations, with strong cash reserves through Sept. 2026.
23h agoSEC 8-KNEUTRAL 50General
Edgewise Therapeutics, Inc. (EWTX) files 8-K
Filed: 2026-11-04 AccNo: 0001104659-26-122654 Size: 249 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
23h agoPR NewswireBULLISH 58Earnings
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – – Dosed first patient in Phase 2 EQUINOX-HFpEF...
Frequently asked questions
Why is EWTX stock moving today?
EDGEWISE THERAPEUTIC (EWTX) is drawing unusual attention today. Our newswire has captured 7 stories on EWTX across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "Raymond James raises Edgewise Therapeutics price target on FDA feedback" (Investing.com Analyst Ratings).
Is EWTX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of EWTX coverage reads 63/100 over 7 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is CDLR down today (-70.59%)
- Why is VCYT down today (-55.24%)
- Why is APP up today (+30.63%)
- Why is ROCK down today (-27.74%)
- Why is TRIP down today (-27.50%)
- Why is LYNX up today (+27.05%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on EWTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier EWTX move explainers: 2026-08-20 · 2026-07-14 · 2026-07-13